A Phase 3 clinical trial (NCT05055908) evaluating pembrolizumab for lung cancer reached its primary completion date on 2025-07-01. The study, titled "Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors," has enrolled 12,000 participants.

Background

Pembrolizumab (Keytruda) is an immune checkpoint inhibitor. This study focuses on its efficacy and biomarker development in the context of lung cancer. The trial investigates pembrolizumab as monotherapy and in combination with pemetrexed.

Trial design

The study, identified as NCT05055908, is a Phase 3 trial with an overall status of RECRUITING, though it has reached its primary completion date. It has a large enrollment target of 12,000 participants. The trial is designed to investigate treatments for Lung Cancer. Interventions include pemetrexed plus pembrolizumab, pembrolizumab alone, and pemetrexed alone. The primary purpose of the study is to identify biomarkers that predict adverse events associated with immune checkpoint inhibitor monotherapy or combination with platinum-based chemotherapy in lung cancer. Specific primary outcomes were not detailed in the provided data.

What this means

The primary completion of this large Phase 3 trial for pembrolizumab in lung cancer signifies a major milestone in the study's progression. With 12,000 participants, the trial is substantial, and reaching primary completion indicates that data collection for the main objectives is complete. Researchers will now proceed with data analysis to evaluate the efficacy and biomarker development for pembrolizumab in lung cancer, both as monotherapy and in combination with pemetrexed. The findings from this study are anticipated to provide important insights into treatment strategies and patient selection in lung cancer.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05055908, titled "Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors," was recorded with a primary completion date of 2025-07-01 on clinicaltrials.gov.